Drugs / Envofolimab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05410197 | Oct 2022 → Aug 2024 | biliary tract cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05148195 | Dec 2021 → Jul 2023 | neoplasm | Jiangsu Simcere Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Envofolimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05410197 ↗ |
| Route | Subcutaneous | “400mg by subcutaneous injection every 3 weeks” NCT05410197 ↗ |